Cotreatment of DLBCL cells with CFZ and vorinostat induces pronounced cell cycle arrest in G2M
| Cell cycle (phase) . | Control . | CFZ . | Vorinostat . | CFZ plus vorinostat . |
|---|---|---|---|---|
| SUDHL4 | ||||
| G0G1 | 45.9 ± 3.8 | 31.9 ± 0.9 | 65.8 ± 1.6 | 5.9 ± 3.4 |
| G2M | 15.1 ± 1.6 | 28.2 ± 1.4* | 15.4 ± 1.2 | 78.7 ± 4.9† |
| S | 35.4 ± 2.8 | 40.4 ± 1.6 | 16.7 ± 1.3 | 15.6 ± 1.7 |
| OCI-LY10 | ||||
| G0G1 | 30.7 ± 1.7 | 23.4 ± 1.6 | 25.4 ± 3.1 | 5.9 ± 1.5 |
| G2M | 12.5 ± 1.5 | 21.8 ± 2.2* | 15.1 ± 1.7 | 50.2 ± 1.7† |
| S | 53.5 ± 4.5 | 54.7 ± 0.7 | 56.4 ± 3.1 | 44.4 ± 1.1 |
| Cell cycle (phase) . | Control . | CFZ . | Vorinostat . | CFZ plus vorinostat . |
|---|---|---|---|---|
| SUDHL4 | ||||
| G0G1 | 45.9 ± 3.8 | 31.9 ± 0.9 | 65.8 ± 1.6 | 5.9 ± 3.4 |
| G2M | 15.1 ± 1.6 | 28.2 ± 1.4* | 15.4 ± 1.2 | 78.7 ± 4.9† |
| S | 35.4 ± 2.8 | 40.4 ± 1.6 | 16.7 ± 1.3 | 15.6 ± 1.7 |
| OCI-LY10 | ||||
| G0G1 | 30.7 ± 1.7 | 23.4 ± 1.6 | 25.4 ± 3.1 | 5.9 ± 1.5 |
| G2M | 12.5 ± 1.5 | 21.8 ± 2.2* | 15.1 ± 1.7 | 50.2 ± 1.7† |
| S | 53.5 ± 4.5 | 54.7 ± 0.7 | 56.4 ± 3.1 | 44.4 ± 1.1 |
SUDHL4 cells were treated with 4.0nM CFZ with or without 1.5μM vorinostat, or OCI- LY10 cells were treated with 7.0nM CFZ with or without 1.5μM vorinostat for 18 hours. After treatment, cells were collected, fixed in ice-cold methanol at a ratio of 1 mL phosphate-buffered saline to 3 mL methanol, and cell-cycle traverse was analyzed by flow cytometry using Modfit software as described in “Cell-cycle analysis.”
DLBCL indicates ; and CFZ, carfilzomib.
Significantly greater than values for untreated control cells (P < .02).
Significantly greater than values for cells treated with CFZ alone (P < .005).